Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANAFRANIL vs BACLOFEN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Clomipramine is a tricyclic antidepressant (TCA) that inhibits the reuptake of serotonin and norepinephrine, with a higher potency for serotonin reuptake inhibition. It also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking properties.
GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.
Obsessive-compulsive disorder (OCD),Off-label: depression, panic disorder, chronic pain, cataplexy associated with narcolepsy, premature ejaculation
Spasticity due to multiple sclerosis (FDA approved),Spinal cord injury (FDA approved),Intrathecal use for severe spasticity of cerebral origin (off-label),Hiccups (off-label),Alcohol withdrawal syndrome (off-label),Trigeminal neuralgia (off-label)
Initial: 25 mg PO tid; increase gradually to 100-150 mg/day. Maximum: 250 mg/day. Maintenance: lowest effective dose.
Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.
Terminal elimination half-life of clomipramine is approximately 21-26 hours; its active metabolite, desmethylclomipramine, has a half-life of approximately 36-42 hours. Steady-state is achieved within 7-14 days.
Terminal half-life: 2.5-4 hours (young adults), 4-8 hours (elderly); clinical context: requires frequent dosing for spasticity.
Primarily hepatic via CYP1A2, CYP3A4, CYP2C19, and CYP2D6; active metabolite desmethylclomipramine formed via N-demethylation.
Metabolized via hepatic deamination by transaminase; primarily excreted unchanged in urine (approximately 70-80%), with minor hepatic metabolism.
Renal (primarily as conjugated metabolites, ~60-70% over 72 hours); fecal (biliary excretion of ~10-20%); <2% excreted unchanged in urine.
Renal: 70-80% unchanged; fecal: <5%; biliary: minimal.
97.6% bound primarily to alpha1-acid glycoprotein and albumin.
30-35% bound to albumin.
Approximately 12-17 L/kg, indicating extensive tissue distribution.
Vd: 0.5-0.7 L/kg; indicates distribution into total body water.
Oral bioavailability is approximately 45-55% due to first-pass metabolism. IV administration yields 100%.
Oral: 70-85% with high variability; intrathecal: 100%.
No specific guidelines. Use with caution in severe renal impairment (Cr Cl <30 m L/min); consider dose reduction based on tolerability.
Cr Cl 30-50 m L/min: reduce dose by 50%; Cr Cl <30 m L/min: avoid use or use with extreme caution, reduce dose by 75%.
Child-Pugh A: no adjustment needed. Child-Pugh B: reduce dose by 50%. Child-Pugh C: contraindicated.
No specific guidelines; use with caution due to potential for increased sedation/neurotoxicity.
Not recommended for children <10 years. For adolescents: initial 25 mg PO daily, increase slowly to 3 mg/kg/day or 100 mg/day maximum (whichever is lower).
Children 2-7 years: initial 2.5 mg orally 4 times daily, increase by 2.5 mg/dose every 3 days to max 40 mg/day; children ≥8 years: initial 5 mg orally 3 times daily, increase as in adults to max 60 mg/day.
Initial: 10 mg PO daily; increase slowly to 30-50 mg/day. Monitor for orthostatic hypotension, sedation, and anticholinergic effects.
Start at low end of dosing range (5 mg twice daily), titrate slowly due to increased risk of sedation, weakness, and cognitive impairment.
Suicidality and Antidepressant Drugs: Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term studies. Closely monitor for clinical worsening, suicidality, or unusual changes in behavior.
Abrupt discontinuation may cause withdrawal symptoms including hallucinations, seizures, and life-threatening hyperpyrexia; taper dose gradually.
May increase risk of suicidal thoughts/behaviors; serotonin syndrome when used with other serotonergic drugs; lowering of seizure threshold; orthostatic hypotension; anticholinergic effects (e.g., urinary retention, blurred vision); cardiac conduction abnormalities; QT prolongation; neuroleptic malignant syndrome; angle-closure glaucoma; hyperpyrexia; withdrawal symptoms upon abrupt discontinuation; use with caution in patients with cardiovascular disease, hepatic impairment, renal impairment, history of seizures, and elderly patients.
May cause CNS depression (drowsiness, sedation) and impair ability to drive or operate machinery.,Risk of withdrawal syndrome including fever, altered mental status, and autonomic instability upon abrupt cessation.,Use with caution in patients with renal impairment; dose adjustment required.,May exacerbate psychiatric disorders; monitor for hallucinations, confusion.,Risk of respiratory depression when combined with other CNS depressants.
Hypersensitivity to clomipramine or other tricyclics; concurrent use or within 14 days of MAO inhibitors; recent myocardial infarction; history of seizure disorder; narrow-angle glaucoma; urinary retention; concurrent use with linezolid or methylene blue.
Hypersensitivity to baclofen.,Intrathecal formulation is contraindicated in patients with active infection or bleeding disorders at lumbar puncture site.,Women who are breastfeeding (relative contraindication).
Avoid grapefruit and grapefruit juice as they may increase clomipramine levels. Take with food to reduce gastric upset. Avoid excessive caffeine; it may increase side effects like anxiety or tremors. Limit alcohol due to additive CNS depression.
No specific food interactions. Avoid alcohol due to additive CNS depression.
First trimester: Limited data; possible increased risk of congenital heart defects (RR ~1.3). Second/third trimester: Risk of neonatal withdrawal syndrome (jitteriness, feeding difficulties, respiratory distress) and persistent pulmonary hypertension of the newborn (PPHN) with late exposure.
First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third trimesters: Risk of neonatal withdrawal (hypertonia, seizures) with chronic maternal use. Avoid unless benefit outweighs risk.
Anafranil (clomipramine) is excreted into breast milk. M/P ratio approximately 0.5-1.0. Relative infant dose estimated 1-2% of maternal weight-adjusted dose. Monitor infant for drowsiness, feeding difficulties, and weight loss. Generally compatible with caution.
Baclofen excreted into breast milk in low concentrations (M/P ratio approximately 0.43). Relative infant dose estimated 0.9% of maternal weight-adjusted dose. Considered compatible with breastfeeding, but monitor infant for sedation and hypotonia.
Due to increased plasma volume and enhanced hepatic metabolism in pregnancy, serum levels may decrease by up to 50%. Consider dose adjustment based on clinical response and trough levels; typical increase by 25-50% may be needed in later pregnancy. Postpartum, reduce dose to prepregnancy levels over 1-2 weeks.
No specific dose adjustments recommended. Increased renal blood flow and GFR in pregnancy may reduce baclofen levels; monitor clinical effect and adjust dose as needed. Avoid abrupt discontinuation due to risk of maternal withdrawal and rebound spasticity.
Anafranil (clomipramine) is a tricyclic antidepressant (TCA) primarily used for obsessive-compulsive disorder (OCD). Monitor for QT prolongation, especially in patients with cardiac risk factors or on other QT-prolonging drugs. Due to anticholinergic effects, use cautiously in elderly, those with BPH, or narrow-angle glaucoma. Start low and titrate slowly to minimize side effects. Therapeutic response may take 2-4 weeks. Do not discontinue abruptly due to withdrawal symptoms.
Abrupt withdrawal can cause severe rebound spasticity, fever, and rhabdomyolysis; taper by 5-10 mg/week. Intrathecal baclofen pumps require careful monitoring for overdose (respiratory depression) or withdrawal. Use with caution in renal impairment (dose adjust for Cr Cl <30 m L/min).
Take exactly as prescribed; do not adjust dose without consulting your doctor.,It may take several weeks to feel the full benefit; do not stop suddenly.,Avoid alcohol and other CNS depressants.,Report any suicidal thoughts, worsening depression, or mood changes immediately.,May cause drowsiness, dizziness, or blurred vision; avoid driving until you know how it affects you.,Dry mouth, constipation, and urinary retention are common; increase fluid intake and dietary fiber.,Use sun protection; this medication can increase sensitivity to sunlight.,Do not take with MAO inhibitors (e.g., linezolid, methylene blue) or within 14 days of stopping them.
Do not stop taking baclofen suddenly; sudden discontinuation can cause serious withdrawal symptoms including hallucinations, seizures, and high fever.,Avoid alcohol and CNS depressants as they increase sedation and risk of falls.,May cause dizziness or drowsiness; avoid driving or operating machinery until you know how it affects you.,Take exactly as prescribed; missed doses can lead to muscle spasms or withdrawal.,Report any unusual muscle stiffness, rapid heart rate, or dark urine immediately.
No interactions on record
"Sevoflurane enhances the inhibitory effects of baclofen on the central nervous system by potentiating GABA-B receptor activity, leading to an increased risk of profound sedation, respiratory depression, and hypotension. This synergistic interaction can result in prolonged recovery from anesthesia and the need for ventilatory support. Clinically, patients may exhibit exaggerated muscle relaxation and a delayed emergence from anesthesia, particularly at higher doses of either agent."
"Concomitant use of etidocaine, an amide-type local anesthetic that blocks voltage-gated sodium channels, and baclofen, a GABAB receptor agonist used for muscle spasticity, may lead to additive central nervous system (CNS) depression and respiratory depression. This interaction results from synergistic depressant effects on the brainstem and spinal cord, increasing the risk of sedation, dizziness, ataxia, and impaired consciousness. Clinically, patients may experience excessive drowsiness, respiratory compromise, and impaired motor coordination, particularly in the elderly or those with pre-existing renal impairment where baclofen accumulation is more likely."
"The coadministration of Baclofen and Metaxalone results in additive central nervous system (CNS) depression due to their shared pharmacodynamic effects on GABAergic and sedative pathways. This combination can potentiate sedation, dizziness, ataxia, and respiratory depression, particularly in elderly patients or those with renal impairment. Clinical outcomes may include increased risk of falls, cognitive impairment, and impaired motor coordination, necessitating cautious dose titration."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANAFRANIL vs BACLOFEN, answered by our medical review team.
ANAFRANIL is a Tricyclic Antidepressant that works by Clomipramine is a tricyclic antidepressant (TCA) that inhibits the reuptake of serotonin and norepinephrine, with a higher potency for serotonin reuptake inhibition. It also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking properties.. BACLOFEN is a Skeletal Muscle Relaxant that works by GABA-B receptor agonist; inhibits monosynaptic and polysynaptic spinal reflexes by hyperpolarizing afferent terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANAFRANIL and BACLOFEN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANAFRANIL is: Initial: 25 mg PO tid; increase gradually to 100-150 mg/day. Maximum: 250 mg/day. Maintenance: lowest effective dose.. The standard adult dose of BACLOFEN is: Initial: 5 mg orally 3 times daily; increase by 5 mg per dose every 3 days to max 80 mg/day (20 mg 4 times daily). Intrathecal: initial test dose 50-100 mcg; for continuous infusion, daily dose typically 300-800 mcg.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANAFRANIL and BACLOFEN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANAFRANIL is classified as Category C. First trimester: Limited data; possible increased risk of congenital heart defects (RR ~1.3). Second/third trimester: Risk of neonatal withdrawal syndrome (jitteriness, feeding dif. BACLOFEN is classified as Category C. First trimester: Limited human data; animal studies show increased fetal malformations (omphalocele, exencephaly) at doses equivalent to human therapeutic range. Second and third t. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.